NeuroBo Pharmaceuticals, Inc. (NRBO)
| Market Cap | 50.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -29.81M |
| Shares Out | 22.20M |
| EPS (ttm) | -1.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 266,799 |
| Open | 1.91 |
| Previous Close | 1.91 |
| Day's Range | 1.88 - 1.94 |
| 52-Week Range | 1.82 - 7.61 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 16.00 (+746.6%) |
| Est. Earnings Date | Nov 11, 2021 |
About NRBO
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an ac...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for NRBO stock is "Buy" and the 12-month stock price forecast is 16.00.
News
Best Penny Stocks to Buy Right Now? Here's 3 For Your Watchlist in October
Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Right Now?
Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving Today
There's loads of hot penny stocks worth checking in on today and we're taking a look at what some of the top movers are doing! The post Hot Penny Stocks: Why NEW, ARDX, WTRH, GSAT and NRBO Are Moving To...
NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase ...
BOSTON, Oct. 13, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...
NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering
BOSTON, Oct. 5, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapie...
NeuroBo Pharmaceuticals Announces $14 Million Registered Direct Offering
BOSTON, Oct. 1, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapie...
NeuroBo Pharmaceuticals Reports Second Quarter 2021 Financial Results
BOSTON, Aug. 16, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...
3 Biotech Penny Stocks That You Need to Know About In 2021
Are these the best biotech penny stocks to watch in 2021? The post 3 Biotech Penny Stocks That You Need to Know About In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt...
LCLP Stock: 10 Reasons Why Penny Stock Battery Maker Life Clips Is Plunging Today
Life Clips (LCLP) stock is falling on Tuesday following an update from the battery company about its recent business announcements. The post LCLP Stock: 10 Reasons Why Penny Stock Battery Maker Life Cli...
Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the Move Today
Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...
NRBO Stock: 6 Things to Know About NeuroBo Pharma as Retail Investors Send Shares Rocketing
Neurobo Pharmaceuticals (NRBO) stock is on the rise Tuesday as retail traders take a liking to the biotechnology company. The post NRBO Stock: 6 Things to Know About NeuroBo Pharma as Retail Investors S...
NeuroBo Pharmaceuticals' Shareholders Elect Hyung Heon Kim and Andrew I. Koven to NeuroBo's Board of Directors
BOSTON, July 12, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapie...
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results
BOSTON, May 17, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies...
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update
BOSTON, April 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapi...
2 Falling Knives to Catch
Wall Street recommends buying shares of NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) and Windtree Therapeutics Inc (NASDAQ:WINT), even though these two securities have shown poor performance over the prior...
NeuroBo Pharmaceuticals Receives Approval for Amendment of Contingent Value Rights for Gemcabene
BOSTON, March 24, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has received approval of an amendment to its Continge...
NeuroBo Pharmaceuticals Closes $10.0 Million Private Placement
BOSTON, Jan. 21, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced the closing of its previously announced private placement of a...
NeuroBo Pharmaceuticals Acquires ANA Therapeutics for Late-Stage Oral Antiviral Development Program
BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutics, a priva...
NeuroBo Pharmaceuticals (NRBO) Surges: Stock Moves 5.2% Higher
NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
NeuroBo Pharmaceuticals Reports Third Quarter 2020 Financial Results
BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...
NeuroBo Pharmaceuticals Reports Second Quarter 2020 Financial Results
BOSTON, Aug. 11, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.
NeuroBo Pharmaceuticals to Join Russell 3000® and Microcap® Indexes
BOSTON, June 16, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapi...